首页> 外国专利> METHOD FOR DIAGNOSING WHETHER PATIENT SUFFERS FROM MULTIPLE HEPATIC DISEASES, AND METHOD FOR DETERMINING PATIENT'S RISK WITH RESPECT TO MULTIPLE HEPATIC DISEASES

METHOD FOR DIAGNOSING WHETHER PATIENT SUFFERS FROM MULTIPLE HEPATIC DISEASES, AND METHOD FOR DETERMINING PATIENT'S RISK WITH RESPECT TO MULTIPLE HEPATIC DISEASES

机译:诊断患有多种肝病的患者的方法,以及针对多种肝病确定患者风险的方法

摘要

The first object of the disclosed invention is method for diagnosing whether a patient suffers from multiple hepatic diseases, where the first hepatic disease was preliminarily diagnosed in the said patient by determining the level of human progastrin (hPG) in a plasma or serum sample of the said patient, at which if threshold value of progastin is at least 400 pM, the said patient is suffering from at least one additional hepatic disease. In addition, described is method for determining patient's risk with respect to multiple hepatic diseases, which includes determination of hPG levels in patient's serum or plasma by means of biochemical analysis and evaluation of relative patient's risk on the basis of the obtained data for one or more hepatic pathologies, where hPG level lower than 100 pM testifies to the fact that the patient is at the "low risk" level for one or more hepatic pathologies; hPG level from 100 to 400 pM testifies to the fact that the patient is at the "high risk" level with respect to presence of cirrhosis with liver cancer or without it and at the "higher risk" level also for presence of hepatitis C, and hPG level higher than 400 pM testifies to the fact that the patient is at the "higher risk" level for presence of liver cancer, cirrhosis and hepatitis C. The patient is also subjected to additional testing with application of other diagnostic means to confirm the fact that the said patient does not have liver cancer, if the said patient has hPG level lower than 100 pM; as well as to additional testing with application of other diagnostic means for liver cancer and/or hepatitis C, if the patient has hPG level from 100 to 400 pM.
机译:所公开的发明的第一目的是用于诊断患者是否患有多种肝病的方法,其中通过确定所述患者的血浆或血清样品中人前胃泌素(hPG)的水平来在所述患者中初步诊断出第一肝病。所述患者,如果前列腺素的阈值至少为400pM,则所述患者正患有至少一种另外的肝病。另外,描述了用于确定关于多种肝病的患者风险的方法,其包括通过生化分析确定患者血清或血浆中hPG水平并基于获得的一种或多种数据评估相对患者的风险。肝病理,其中hPG水平低于100 pM证明患者处于一种或多种肝病理的“低风险”水平; hPG从100到400 pM的水平证明,患者有或没有肝癌的肝硬化患者处于“高风险”水平,而丙型肝炎患者也处于“较高风险”水平。 hPG高于400 pM证明患者处于肝癌,肝硬化和丙型肝炎的“较高风险”水平。该患者还接受其他诊断手段的进一步测试,以证实这一事实。如果所述患者的hPG水平低于100pM,则该患者没有肝癌;如果患者的hPG水平在100至400 pM之间,则应进行其他肝癌和/或丙型肝炎诊断方法的检测。

著录项

  • 公开/公告号EA023653B1

    专利类型

  • 公开/公告日2016-06-30

    原文格式PDF

  • 申请/专利权人 LES LABORATOIRES SERVIER;

    申请/专利号EA20120000997

  • 发明设计人 FLOCH JEAN-FRANCOIS;HOUHOU LEILA;

    申请日2011-01-07

  • 分类号G01N33/74;

  • 国家 EA

  • 入库时间 2022-08-21 14:26:15

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号